�Next generation anticoagulant and antiplatelet agents have shown superiority o'er the stream market leaders in clinical studies and are to challenge them before generics.
The Business Intelligence firm La Merie S.L. reported in its most late update of the Antithrombotics Competitor Pipeline that gross sales of the two leading antithrombotics enoxaparin and clopidogrel are rather being challenged by improved innovator drugs than by cheaper generics. The strapping market of major branded antithrombotics in 2007 was US$ 14.9 bln and attracts many companies to acquire innovative successors.
The leading anticoagulant enoxaparin is already being challenged by market launch of the starting time oral conduct thrombin inhibitor from Boehringer Ingelheim.
Oral direct Factor Xa inhibitors are the leading class of anticoagulants having shown superior effects over enoxaparin. Bayer's rivaroxaban is under regulatory review in the US and EU and leads the field with further 11 F. Xa inhibitors in clinical development. Oral antiplatelet agent clopidogrel from Sanofi-Aventis and Bristol-Myer Squibb posted 2007 gross revenue of US$ 8.5 bln and faces competition from more than 14 clinical stage compounds directed at a variety of different targets. Prasugrel from Lilly and Daiichi Sankyo recently was shown to be superior over clopidogrel in reduction the risk of coronary in-stent thrombosis. These results and more than were found in a search conducted by La Merie Business Intelligence.
The evaluation can be acquired at La Merie's on-line store.
The report provides information on competitor projects in development as novel anticoagulants and antiplatelet agents. Current major targets in anticoagulant R&D are improved drug obstetrical delivery of low-molecular weigh heparins, improved antithrombin-III agonists, thrombin inhibitors and modulators, indirect and conduct F. Xa inhibitors, double thrombin and F. Xa inhibitors, other factors in the coagulation cascade (F. VIII, F. XI, IX, TF/VII). Antiplatelet R&D focuses on the platelet ADP and thrombin receptor, just new targets such as the von Willebrand Factor / glycoprotein Ib and VI are gaining system of weights among other new antiplatet approaches. Antithrombotic targets such as PAI-1 and TAFIa are static in the clinical exploratory phase.
About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information see www.lamerie.com.
About PipelineReview.com
PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence focused on Research and Development in the Biopharmaceutical Industry. Visitors of PipelineReview.com will line up R&D relevant press releases and pot receive selected R&D word from one or more of the site's News Channels. La Merie Daily and La Merie Biologics conveniently bring in via email a daily or weekly selection of the most interesting intelligence from biopharmaceutical R&D. For more information visit www.pipelinereview.com.
More info
